{{$DoctorName}} @if(isset(session()->get('doctor')['vCentralCode'])) {{session()->get('doctor')['vCentralCode']}} @endif
@if(isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{$ActivityTypeName}}

{{$ActivityName}}

@csrf
@if(isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Patient {{$iPatientNo}}

(Kindly fill in the relevant information or tick, as appropriate.)

  1. As per your clinical practice, what is the approximate number of patients diagnosed with neovascular (wet) age-related macular degeneration (AMD) every month?

  2. As per your clinical practice, what is the approximate number of patients diagnosed with Diabetic Macular Edema every month?

  3. What is the approximate number of patients diagnosed with neovascular (wet) age-related macular degeneration (AMD) requiring Anti VEGF Agents as per your practice?

  4. What is the approximate number of patients with diagnosed with Diabetic Macular Edema requiring Anti VEGF Agents as per your practice?

  5. As per your clinical practice, kindly rank your preferred Anti- Vascular endothelial growth factor (VEGF) agent in patients diagnosed with neovascular (wet) age-related macular degeneration (AMD)?
    (Kindly specify the rankings in front of each agent as per your preference)

  6. What is the approximate number of patients diagnosed with neovascular (wet) age-related macular degeneration (AMD) requiring Ranibizumab Solution for Injection 10 mg/mL as per your practice?

  7. Which are the patient profiles with neovascular (wet) age-related macular degeneration (AMD) who might benefit more with Ranibizumab Solution Injection 10 mg/mL as compared with other anti-VEGF inhbitor?
  8. As per your clinical practice, kindly provide the approximate break-up of usage of Ranibizumab Solution for Injection 10 mg/mL in percentages for the below indications? (Please tick all the applicable options)

    9. A.  Neovascular (wet) age-related macular degeneration (AMD)
    %

    B.  Diabetic Macular Edema
    %

    C.  Myopic Choroidal Neovascularization
    %

    D.  Macular Edema Following Retinal Vein Occlusion (RVO)
    %

    Total

    		 100%
  9. How frequently are the patients required to follow-up in the below indications?
    10. Neovascular (wet) age-related
    macular degeneration (AMD)     		Diabetic Macular Edema

    A.  Every month

    B.  Every 3-6 months

    C.  Every yearly

    D.  Once every 2 years

    E.  Any other- please specify

  10. How would you rate the efficacy of Oceva (Biosimilar Ranibizumab) in neovascular (wet) age-related macular degeneration (AMD)?

  11. How would you rate the tolerability of Oceva (Biosimilar Ranibizumab) in neovascular (wet) age- related macular degeneration (AMD)?

  12. What is advantage of Ranibizumab Solution for Injection 10 mg/mL over other ant-VEGF agents as per observations in your practice?